We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
Cayman C16 Glucosylceramide-d3 (d18:1/16:0-d3)


Product Description
C16 Glucosylceramide-d3 is intended for use as an internal standard for the quantification of C16 glucosylceramide by GC- or LC-MS. C16 glucosylceramide is an endogenous bioactive sphingolipid., It is a precursor in the synthesis of C16 lactosylceramide (Item No. ) that is formed via metabolism of C16 ceramide (Item No. ) by glucosylceramide synthase. Inhalation of C16 glucosylceramide reduces lung colonization by P. aeruginosa and increases survival in a mouse model of cystic fibrosis. C16 Glucosylceramide levels are elevated in the plasma of Parkinsons disease patients with cognitive impairments. As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1533]
WARNING This product is not for human or veterinary use.
Technical Information
- N-ω-CD3-Hexadecanoyl-glucopsychosine
- GluCer(d18:1/16:0-d3)
- Glucosylceramide-d3 (d18:1/16:0-d3)
- Chloroform:Methanol (2:1): Soluble
Shipping & Storage Information
| SKU | CAYM-24621-1 |
|---|---|
| Supplier Part Number | 24621-1 |
| UM | EA |
| UNSPSC | 12352200 |
| Manufacturer | Cayman |
| MSDS URL | Click here |
| Temperature | -20 |
| Refrigerated-Frozen | Y |
| CountryOfOrigin | United States |
| ProductLine | CAYM |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 5 |
| Hazardous | N |
| Energy Star | No |
| Green | No |
| Controlled | N |

